Biotech, RNA Interference, Drugs
MDRNA Nasal Spray Gets FDA Nod
Luke Timmerman 6/9/09
Bothell, WA-based MDRNA (NASDAQ: MRNA) said today that a generic calcitonin nasal spray for osteoporosis has received FDA approval, and has been introduced to the market. The Bothell, WA-based company sold the product in March to Woodcliff Lake, NJ-based Par Pharmaceutical (NYSE: PRX), although MDRNA still stands to receive an undisclosed profit share from the product over the next five years. MDRNA has switched its strategy from developing nasal spray products to RNA interference technology.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
